- PR Newswire•3 hours agoIpsen Biopharmaceuticals, Inc. Announces Nine Poster Presentations at the 2016 North American Neuroendocrine Tumor Society (NANETS) Symposium
BASKING RIDGE, N.J., Sept. 30, 2016 /PRNewswire/ -- Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that nine studies have been selected for poster ...
- PR Newswire•9 days agoIpsen Announces Data Presentation for Dysport® (abobotulinumtoxinA) at American Academy of Cerebral Palsy and Developmental Medicine
ADR: IPSEY), today announced that an additional data analysis regarding the safety and efficacy of repeated treatment sessions of Dysport® (abobotulinumtoxinA) in children (aged 2 and older) with lower limb spasticity will be presented at the annual meeting of the American Academy of Cerebral Palsy and Developmental Medicine (AACPDM) being held in Hollywood, Florida, September 20 – 24, 2016. The data will be shared in an oral presentation of the results of an open label extension of a multicenter, prospective, double-blind, randomized, placebo-controlled study assessing Dysport® in pediatric patients 2 to 17 years of age with lower limb spasticity because of cerebral palsy causing dynamic equinus foot deformity. "We are pleased to present this data at this year's AACPDM meeting, following the FDA's recent approval of Dysport® for the treatment of lower limb spasticity in pediatric patients aged two and older," said Cynthia Schwalm, EVP, North America Commercial Operations, Ipsen.
Ipsen S.A. (IPSEY)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||21.65|
|Avg Vol (3m)||395|
|Dividend & Yield||0.24 (1.41%)|